Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Similar documents
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Spotlight on Valvular Heart Disease Guidelines

Stress Testing in Valvular Disease

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University

Valvular Guidelines: The Past, the Present, the Future

Mixed aortic valve disease

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Indicator Mild Moderate Severe

Valvular Heart Disease: Assessment and Timing of Intervention. Graham Cole Consultant Cardiologist Imperial College Healthcare NHS Trust

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

2017 ESC/EACTS Guidelines for the management of valvular heart disease

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

Indication, Timing, Assessment and Update on TAVI

Comprehensive Echo Assessment of Aortic Stenosis

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Valvular Heart Disease

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

TAVR: Echo Measurements Pre, Post And Intra Procedure

In Process, Unpublished STS/ACC TVT Registry Manuscripts

Aortic Regurgitation & Aorta Evaluation

Welcome 17 Michigan TAVR Participating Hospitals!

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

ESC/EACTS Guidelines for the Management of Valvular Heart Disease

Aortic Valve Stenosis and TAVR: Putting it all together.

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

Aortic valve implantation using the femoral and apical access: a single center experience.

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

Aortic Stenosis: Background

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Aortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

Aortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants

Transcatheter Aortic Valve Replacement

Low Gradient Severe? AS

A Health Care Professional s Guide Aortic Stenosis in Seniors

Cardiac catheterisation in AS

The prevalence of calcific aortic valve disease approaches. Compendium. Current Management of Calcific Aortic Stenosis

Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504

TAVR SPRING 2017 The evolution of TAVR

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Potential conflicts of interest

Policy Specific Section: March 30, 2012 March 7, 2013

Aortic Valve Stenosis: When stress TTE and/or TEE is required to make the diagnosis and guide treatment

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Transcatheter aortic valve implantation for aortic stenosis

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

How to Assess and Treat Obstructive Lesions

SONOGRAPHER & NURSE LED VALVE CLINICS

TAVR in 2020: What is Next!!!!

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies

TAVR IN INTERMEDIATE-RISK PATIENTS

Cardiac MRI in ACHD What We. ACHD Patients

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Worldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates

Transcatheter Aortic Valve Replacement TAVR

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

Aortic Valve Replacement Improves Outcome in Patients with Preserved Ejection Fraction: PRO!

Emergency TAVI: Does It Exist? Is the Risk Higher?

1-YEAR OUTCOMES FROM JOHN WEBB, MD

In Process, Unpublished STS/ACC TVT Registry Manuscripts

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

Which one of the following echocardiographic profiles most strongly indicates the need for aortic valve replacement? FS [

Primary Mitral Regurgitation

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Nothing to Disclose. Questions. Disclosure Asymptomatic Severe Aortic Stenosis: (When) Should One Intervene? Paul Wood at the Nathanson Lecture, 1958

7. Echocardiography Appropriate Use Criteria (by Indication)

Echocardiographic Evaluation of Aortic Valve Prosthesis

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

Aortic stenosis aetiology: morphology of calcific AS,

Echocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Echocardiographic Evaluation of Aortic Valve Prosthesis

APOLLO TMVR Trial Update: Case Presentation

Risk Patients Before TAVI or AVR

For the SURTAVI Investigators

Case Presentations TAVR: The Good Bad and The Ugly

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:

Management of significant asymptomatic aortic stenosis. Alec Vahanian Bichat Hospital University Paris VII Paris, France

Outcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era

Managing the Low Output Low Gradient Aortic Stenosis Patient

Medical Apps for Cardiology Uses. There s an App for That!

Essential Support for a Structural Heart Program: The Valve and Structural Heart Clinic

Transcription:

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center

Disclosure Dr. Burke has no conflicts of interest to report.

Aortic Stenosis Aortic stenosis is the most common primary valve disease leading to surgery or catheter intervention Due to the aging population, prevalence is increasing

Valve intervention should be decided by a Valve Heart Team - integrated, multidisciplinary approach including surgeons and cardiologists

Severe aortic stenosis Asymptomatic severe aortic stenosis Low flow-low gradient aortic stenosis Surgical aortic valve replacement (SAVR) versus transcatheter aortic valve replacement (TAVR)

Severe Aortic Stenosis High gradient Severe Peak velocity > 4 m/s Mean gradient > 40 mmhg Valve area < 1 cm 2

Severe Aortic Stenosis All symptomatic patients require aortic valve replacement Exceptions: Severe comorbidities intervention unlikely to improve quality of life Survival less than one year No lower limit on left ventricular ejection fraction

Symptomatic Severe Aortic Stenosis Aortic valve replacement indicated No medical treatment can improve outcome Statins do not affect progression Do not exercise a patient with symptomatic severe aortic stenosis

Severe aortic stenosis Asymptomatic severe aortic stenosis Low flow-low gradient aortic stenosis Surgical aortic valve replacement (SAVR) versus transcutaneous aortic valve replacement (TAVR)

Asymptomatic Severe Aortic Stenosis Aortic valve replacement indications: Depressed left ventricular systolic function not due to other cause Exercise test symptoms clearly related to aortic stenosis Exercise test BP drop to below baseline Peak velocity > 5.5 m/s (ACC > 5 m/s or mean gradient > 60 mm) Severe valve calcification and rapid progression of stenosis/gradient

Asymptomatic Severe Aortic Stenosis Aortic valve replacement indications: BNP level > 3 x normal PA systolic > 60 mmhg Deleted from 2012 Guidelines Increase in aortic gradient > 20 mm with exercise Excessive LV hypertrophy

Asymptomatic Severe Aortic Stenosis Predictors of symptom development and adverse outcomes Older age Atherosclerotic risk factors Valve calcification Peak aortic jet velocity Rate of hemodynamic progression Increase in > 20 mm Hg gradient with exercise Excessive LV hypertrophy Abnormal longitudinal LV function Pulmonary hypertension Elevated BNP

Asymptomatic Severe Aortic Stenosis Predictors of symptom development and adverse outcomes Early elective surgery in such instances low operative risk Watchful waiting safe Early surgery unlikely to be beneficial

Asymptomatic Aortic Stenosis Wide variability in rate of progression Patient education Need for regular follow-up Report symptoms as soon as they develop Stress testing should determine recommended level of physical activity

Asymptomatic Aortic Stenosis Frequency of Echocardiography Severe - every 6-12 months Moderate - every 1-2 years Mild and Moderate aortic stenosis with significant calcification - yearly Younger patient - mild stenosis and little or no calcification every 2-5 years

Severe aortic stenosis Asymptomatic severe aortic stenosis Low flow-low gradient aortic stenosis Surgical aortic valve replacement (SAVR) versus transcutaneous aortic valve replacement (TAVR)

Low Flow, Low Gradient Aortic Stenosis with Reduced Ejection Fraction (< 50%) Stroke volume index < 35 ml/m 2 Mean gradient < 40 mmhg Peak velocity < 4 m/s Valve area < 1cm 2

Low Flow, Low Gradient with Reduced Ejection Fraction Dobutamine echocardiogram separates: Severe aortic stenosis Pseuodosevere aortic stenosis No contractile reserve

Low Flow, Low Gradient Aortic Stenosis with Reduced Ejection Fraction Dobutamine contractile reserve assessment results in: Increase of stroke volume > 20% Mean gradient > 40 mmhg Peak velocity > 4 m/s Valve area remains < 1cm 2 Diagnosis: severe aortic stenosis Treatment: aortic valve replacement

Low Flow, Low Gradient With Reduced Ejection Fraction Dobutamine results in: Increase in stroke volume > 20% Mean gradient remains < 40 mmhg Peak velocity remains < 4 m/s Valve area now calculates > 1cm 2 Diagnosis: Pseudosevere aortic stenosis Treatment: Conventional treatment for heart failure

Low Flow, Low Gradient With Reduced Ejection Fraction Without Contractile (Flow) Reserve Dobutamine results in: Inability to increase stroke volume 20% Mean gradient remains < 40 mmhg Peak velocity remains < 4 m/s Valve area remains < 1cm 2 Diagnosis: Uncertain if severe aortic stenosis or not

Low Flow, Low Gradient With Reduced Ejection Fraction Without Contractile (Flow) Reserve Further Evaluation: Consider degree of valve calcification by multislice CT Severe AS likely: Men > 2000 Women > 1200 Severe AS unlikely: Men < 1600 Women < 800 Treatment: This group does poorly with medical or surgical treatment Consider aortic valve replacement if CT scans confirms severe calcification

Low Flow, Low Gradient Aortic Stenosis with Preserved Ejection Fraction (> 50%) Stroke volume index < 35 ml/m 2 Mean gradient < 40 mm Peak velocity < 4 m/s Valve area < 1 cm 2 Seen in elderly Small LV cavity Marked LV hypertrophy Often with hypertension

Low Flow, Low Gradient Aortic Stenosis with Preserved Ejection Fraction (> 50%) Evaluation: MUST exclude measurement errors for low stroke volume by echocardiographic findings (LVOT measurement by 3D, TEE, CT, CMR) Consider degree of valve calcification by multislice CT Do not perform Dobutamine infusion Treatment: Consider aortic valve replacement if corrobative testing confirms low stroke volume and severe valve calcification

Normal flow, low gradient aortic stenosis with preserved ejection fraction (> 50%) Stroke volume index > 35 ml/m 2 Mean gradient < 40 mmhg Peak velocity < 4 m/s Valve area > 1cm 2 Diagnosis: Moderate aortic stenosis Recommendation: serial follow-up

Aortic Stenosis Retrograde LV catheterization to assess aortic stenosis severity is no longer routinely performed Its use is restricted to inconclusive non-invasive investigation

Severe aortic stenosis Asymptomatic severe aortic stenosis Low flow-low gradient aortic stenosis Surgical aortic valve replacement (SAVR) versus transcatheter aortic valve replacement (TAVR)

SAVR vs. TAVR TAVR data limited Patients < 75 Surgical low risk group Biscuspid valves Long-term data lacking (SAVR has shown longterm proven durability) TAVR may be considered for bioprosthesis failure SAVR not TAVR is indicated at present for: Low risk patients* Asymptomatic patients* *Ongoing trials Partner 3 and Early TAVR

TAVR vs. SAVR Complications Higher with TAVR Vascular complications Pacemaker implantation Paravalvular regurgitation Higher with SAVR Severe bleeding Acute kidney injury New onset atrial fibrillation Equal Stroke risk

SAVR vs. TAVR STS Score Risk High > 8% Intermediate 4-8% Low < 4% Other Risks Porcelain aorta Prior chest irradiation Frailty Hostile chest, especially if LIMA crossing sternum

SAVR with CABG or Aortic Root Surgery Moderate aortic stenosis Baseline peak gradient > 20-30 mm or peak velocity > 3 m/s in patient < 70 years old Average rate of progression > 5 mmhg/year

Balloon Aortic Valvuloplasty Bridge to SAVR or TAVR in hemodynamically unstable patients Patients with symptomatic severe aortic stenosis who require urgent, major noncardiac surgery Severe aortic stenosis with other potential causes for symptoms, e.g. lung disease or severe myocardial dysfunction resulting in other organ dysfunction, e.g. pre-renal insufficiency, that may be reversible with valvuloplasty - can escalate to TAVR

Atrial Fibrillation and Novel Oral Anticoagulants Aortic stenosis Subgroup analysis of randomized trials support their use Aortic bioprosthesis Guidelines (absence of data) support their use > 3 months after implantation

Aortic Regurgitation No updates in 2017 ACC/AHA document

Aortic Regurgitation Difficult to interpret as severe Vena contracta > 6 mm EROA > 30 cc Regurgitant volume > 60 cc CMR provides accurate measures of regurgitant volume and regurgitant fraction

Aortic Regurgitation Chronic and severe Left ventricle should be dilated Holodiastolic flow reversal in descending aorta (> 20 cm/s) Pressure half time < 200 ms

Severe Chronic Aortic Regurgitation Surgical Indications Symptoms Depressed LVEF (< 50%) Dilated left ventricle LVEDD > 65-70 mm LVESD > 50 mm (> 25 mm/m 2 BSA) Moderate or severe aortic regurgitation while undergoing other cardiac surgery

Aortic Regurgitation Serial testing Mild to moderate yearly exam Severe every 6 months Moderate echocardiogram every 1-2 years Mild echocardiogram every 3-5 years

Conclusions Severe Aortic Stenosis SAVR vs TAVR Evaluation by a Multidisciplinary Heart Team SAVR for low surgical risk SAVR for severe aortic stenosis asymptomatic patients who meet other criteria TAVR for patients with prohibitive surgical risk and life expectancy > 1 year

Conclusions TAVR or SAVR for high or intermediate risk patients The indication for TAVR are expanding in clinical trials and clinical practice Shared-Decision Making - Patient want TAVR - determining when to withhold TAVR is difficult